Dexamethasone or prednisolone for asthma exacerbations in children: a cost-effectiveness analysis

Vista sencilla de ítem
dc.contributor.authorRodríguez-Martínez, Carlos E.
dc.contributor.authorSossa-Briceño, Mónica P.
dc.contributor.authorCastro-Rodriguez, Jose A.
dc.date.accessioned2020-07-10T19:36:20Z
dc.date.available2020-07-10T19:36:20Z
dc.description.abstractenglishObjectives Although a short course (ie, 3 to 5 days) of orally administered prednisolone is a common and widely accepted practice among clinicians for administering systemic corticosteroids in pediatric acute asthma, oral dexamethasone for 1 to 2 days is an attractive alternative to prednisolone due to its better palatability and compliance. However, a cost‐effectiveness analysis regarding the use of dexamethasone compared to prednisolone is not sufficient, especially in lower‐ and middle‐income countries. The objective of this study was to analyze the cost‐effectiveness of prednisolone vs oral dexamethasone for treating pediatric asthma exacerbations. Methods Using a decision‐analysis model, we analyzed the cost‐effectiveness of prednisolone vs oral dexamethasone for treating acute pediatric asthma. Effectiveness parameters were derived from a systematic review of the published literature. Data for costs were acquired from hospital accounts and from an official national database, the national manual of drug prices in Colombia. The study was carried out from a Colombian third‐party payer perspective. The principal outcome of the model was the avoidance of hospitalization. Results The base‐case analysis showed that compared to dexamethasone, administering prednisolone was associated with lower overall treatment costs (US$93.97 vs US$104.91 mean cost per patient) without a significant difference in the probability of hospitalization avoided (.9108 vs .9108). Conclusions The present study shows that in Colombia, a middle‐income country, compared with oral dexamethasone, the use of prednisolone for treating acute pediatric asthma is cost‐effective, yielding a similar probability of hospitalization at lesser overall costs.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1002/ppul.24817
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1099-0496
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3447
dc.language.isoeng
dc.publisherWiley-Blackwellspa
dc.publisher.journalPediatric Pulmonologyspa
dc.relation.ispartofseriesPediatric Pulmonology, 1099-0496, 2020spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/abs/10.1002/ppul.24817
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2020-05-11
dc.rights.localAcceso abiertospa
dc.subject.decsPrednisolonaspa
dc.subject.decsCorticoesteroidesspa
dc.subject.decsDexametasonaspa
dc.subject.keywordsAcute asthmaspa
dc.subject.keywordsChildrenspa
dc.subject.keywordsCost-effectivenessspa
dc.titleDexamethasone or prednisolone for asthma exacerbations in children: a cost-effectiveness analysisspa
dc.title.translatedDexamethasone or prednisolone for asthma exacerbations in children: a cost-effectiveness analysisspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos